Details der Publikation - ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma

ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:30
Enthalten in:	Annals of surgical oncology - 30(2023), 5 vom: 04. März, Seite 2791-2792

Sprache:	Englisch

Beteiligte Personen:	Zhu, Xiao-Dong [VerfasserIn] Huang, Cheng [VerfasserIn] Shen, Ying-Hao [VerfasserIn] Xu, Bin [VerfasserIn] Ge, Ning-Ling [VerfasserIn] Ji, Yuan [VerfasserIn] Qu, Xu-Dong [VerfasserIn] Chen, Lingli [VerfasserIn] Chen, Yi [VerfasserIn] Li, Mei-Ling [VerfasserIn] Zhu, Jin-Jin [VerfasserIn] Tang, Zhao-You [VerfasserIn] Zhou, Jian [VerfasserIn] Fan, Jia [VerfasserIn] Sun, Hui-Chuan [VerfasserIn]

Links:	Volltext [lizenzpflichtig]

Anmerkungen:	© Society of Surgical Oncology 2023

doi:	10.1245/s10434-022-12653-3

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC213437702X

Internformat


LEADER	01000naa a22002652 4500
001	OLC213437702X
003	DE-627
005	20230510161223.0
007	cr uuu---uuuuu
008	230510s2023 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1245/s10434-022-12653-3 \|2 doi
035			\|a (DE-627)OLC213437702X
035			\|a (DE-He213)s10434-022-12653-3-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
100	1		\|a Zhu, Xiao-Dong \|e verfasserin \|4 aut
245	1	0	\|a ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © Society of Surgical Oncology 2023
700	1		\|a Huang, Cheng \|4 aut
700	1		\|a Shen, Ying-Hao \|4 aut
700	1		\|a Xu, Bin \|4 aut
700	1		\|a Ge, Ning-Ling \|4 aut
700	1		\|a Ji, Yuan \|4 aut
700	1		\|a Qu, Xu-Dong \|4 aut
700	1		\|a Chen, Lingli \|4 aut
700	1		\|a Chen, Yi \|4 aut
700	1		\|a Li, Mei-Ling \|4 aut
700	1		\|a Zhu, Jin-Jin \|4 aut
700	1		\|a Tang, Zhao-You \|4 aut
700	1		\|a Zhou, Jian \|4 aut
700	1		\|a Fan, Jia \|4 aut
700	1		\|a Sun, Hui-Chuan \|4 aut
773	0	8	\|i Enthalten in \|t Annals of surgical oncology \|d Springer International Publishing, 1994 \|g 30(2023), 5 vom: 04. März, Seite 2791-2792 \|h Online-Ressource \|w (DE-627)343969947 \|w (DE-600)2074021-9 \|w (DE-576)099879212 \|x 1534-4681 \|7 nnns
773	1	8	\|g volume:30 \|g year:2023 \|g number:5 \|g day:04 \|g month:03 \|g pages:2791-2792
856	4	0	\|u https://dx.doi.org/10.1245/s10434-022-12653-3 \|z lizenzpflichtig \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_187
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_250
912			\|a GBV_ILN_281
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_702
912			\|a GBV_ILN_711
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2004
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2038
912			\|a GBV_ILN_2039
912			\|a GBV_ILN_2044
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2049
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2106
912			\|a GBV_ILN_2107
912			\|a GBV_ILN_2108
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2112
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2118
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2136
912			\|a GBV_ILN_2143
912			\|a GBV_ILN_2144
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2153
912			\|a GBV_ILN_2188
912			\|a GBV_ILN_2190
912			\|a GBV_ILN_2232
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2433
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2474
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4328
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4334
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 30 \|j 2023 \|e 5 \|b 04 \|c 03 \|h 2791-2792

ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände